Clinical trial registry record

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated October 6, 2020.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02461771
Last registry update
October 6, 2020
Status
Completed
Phase
Phase 1
Sponsor
Apellis Pharmaceuticals, Inc.
Enrollment
13
Countries
United States, Australia
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
13
Population
ALL · 50 Years
Duration
2015-01-28 to 2016-03-08
Intervention
Pegcetacoplan
Comparator
Not reported
Outcomes measured
Number of Subjects Who Experienced Ocular and Systemic Adverse Events (AEs), Including by Severity — Day 1 to Day 113; Number of Dose Limiting Toxicities (DLTs) — Day 1 to Day 15; Median Area Under the Serum Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC[0-t]) — Predo…; Median Dose Normalized AUC(0-t) — Predose (screening), postdose Day 3 to Day 113; Maximum Observed Serum Concentration (Cmax) — Predose (screening), postdose Day 3 to Day 113; Median Dose Normalized Cmax — Predose (screening), postdose Day 3 to Day 113; Median Time to the Maximum Measured Serum Concentration (Tmax) — Predose (screening), postdose Day 3 to Day 113; Median Change From Baseline in Visual Acuity for the Study Eye — Day 1 to Day 113; Median Change From Baseline in Central Retinal Thickness, Central Retinal Lesion Thickness and Central Subfield Thickne…; Median Change From Baseline in Macular Cube Volume in the Study Eye — Day 1 to Day 113
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 60%Source terminology contains a controlled topic term. Source terminology supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON